Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

This study aims to compare the efficacy and safety of short-course definitive concurrent chemoradiotherapy plus immunotherapy followed by immunotherapy maintenance versus short-course definitive chemoradiotherapy plus immunotherapy maintenance in the treatment of locally advanced unresectable esophageal squamous cell carcinoma, and to exploratorily identify molecular biomarkers associated with treatment efficacy and toxicity.

Trial Details

NCT ID
NCT07530094
Phase
PHASE2
Sponsor
Ning Jiang, M.D./Ph.D.
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Camrelizumab
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • The patient or their legal representative is able to sign the written informed consent form and understands and agrees to comply with the study req…
  • Age ≥ 18 years and \< 75 years at the time of signing the informed consent form, regardless of gender;
  • Histologically confirmed esophageal squamous cell carcinoma, confirmed by imaging examinations such as CT, MRI, or PET-CT as locally advanced unres…
  • Estimated life expectancy of at least 6 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →